See every side of every news story
Published loading...Updated

End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader

“What’s in a name? That which we call a rose by any other name would smell as sweet,” Juliet famously observed in Shakespeare’s Romeo and Juliet. More than 400 years later, Fujifilm’s Life Sciences Group is renaming two of its companies, in a rebranding intended to position parent company Fujifilm as a strategic partner to drug and vaccine developers across the development life cycle. Lars Petersen, Fujifilm Biotechnologies president and CEO Fuj…

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

GEN - Genetic Engineering and Biotechnology News… broke the news in on Tuesday, July 8, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.